SCHEMBL30830316

SCHEMBL30830316

CC(C)(C)OC(=O)N[C@H]1CSc2ccc(C(=O)NNC(=O)C(C)(C)S(C)(=O)=O)cc2NC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.36
▸ HDAC1 Q13547 2/20 0.36
▸ HDAC8 Q9BY41 2/20 0.36
▸ HDAC6 Q9UBN7 2/20 0.36
▸ HPGD P15428 2/20 0.35
▸ LMNA P02545 5/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ GAA P10253 2/20 0.34
▸ NPC1 O15118 4/20 0.34
▸ RAB9A P51151 4/20 0.34
▸ KDM4E B2RXH2 4/20 0.33
▸ HTT P42858 3/20 0.33
▸ MAPT P10636 3/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ POLB P06746 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29796820 0.90 HDAC1 (0.39) KMT2AHDAC1HDAC8HDAC6HPGD
SCHEMBL26962726 0.90 HDAC1 (0.39) KMT2AHDAC1HDAC8HDAC6HPGD
SCHEMBL31375584 0.86 KMT2A (0.36) KMT2AHDAC1HDAC8HDAC6HPGD
SCHEMBL31628211 0.86 KMT2A (0.36) KMT2AHDAC1HDAC8HDAC6HPGD
SCHEMBL30830313 0.85 GAA (0.34) GAA
SCHEMBL31628166 0.85 HPGD (0.36) KMT2AHDAC1HDAC8HDAC6HPGD
SCHEMBL26962078 0.84 HPGD (0.41) KMT2AHDAC1HDAC8HDAC6HPGD
SCHEMBL29796987 0.84 HPGD (0.41) KMT2AHDAC1HDAC8HDAC6HPGD
SCHEMBL20264133 0.82 SMN1; SMN2 (0.48) KMT2AHDAC1HDAC8HDAC6HPGD
SCHEMBL31375523 0.82 KMT2A (0.36) KMT2AHDAC1HDAC8HDAC6HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035364-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2026-02-05 — — US disclosed
EP-4568958-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-06-18 — — EP disclosed
WO-2024033388-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035364-A1 BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES SCN1B, SCN2B, SCN11A KMT2A 1058/4885HDAC1 298/4885HDAC8 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback